Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual MeetingGlobeNewsWire • 09/26/19
Why Duluth Holdings, Tailored Brands, and Adverum Biotechnologies Slumped TodayThe Motley Fool • 09/12/19
Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMDGlobeNewsWire • 09/12/19
Adverum Biotechnologies, Inc. (ADVM) CEO Leone Patterson on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/09/19
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 08/01/19
Adverum Biotechnologies: Large Market Opportunity, Key Data Presentation In FocusSeeking Alpha • 07/29/19
Is the Options Market Predicting a Spike in Adverum (ADVM) Stock?Zacks Investment Research • 07/26/19
Adverum: Speculative Gene Therapy Play With In-House Capabilities Targeting The Validated And Attractive Ocular SpaceSeeking Alpha • 06/24/19
Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?Zacks Investment Research • 05/24/19
Adverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy PathSeeking Alpha • 04/17/19